FeesSafety
Pluang+

Caribou Biosciences to present clinical data on CAR-T therapies despite halting their development.

Market News
04 Nov 2026, 16:00 WIB
GlobeNewsWire
View Source
Neutral
Caribou Biosciences to present clinical data on CAR-T therapies despite halting their development.

Caribou Biosciences announced presentations of clinical data for its allogeneic CAR-T therapies, vispa-cel and CB-011, at the 2026 ASH Annual Meeting. This comes after the company decided to discontinue further development of these programs due to challenging financing conditions. The presentations will share important clinical findings on treatments for relapsed or refractory B cell non-Hodgkin lymphoma and multiple myeloma. Despite halting development, Caribou aims to communicate the therapies' safety and efficacy to the medical community.

Caribou Biosciences' recent announcement on clinical data presentations at the 2026 ASH Annual Meeting provides context for health sector interest. For readers following health stocks, here is Pluang's market snapshot as of Nov 04, 2026 20:41 WIB: out of 150 priced health-sector US stocks, 127 rose and 19 fell. Notable movers include NUWE at USD 5.25 with a 1-day change of -11.17% and 100% sell order activity, OSCR at USD 35.45 up 9.38% with 84% buy order activity, and HCA at USD 496.00 up 7.16% with a typical hold time of 77 days.

More News

Kelly Technology + Motion Recruitment named Leader by Everest Group for US IT staffing and consulting excellence

Kelly Technology + Motion Recruitment named Leader by Everest Group for US IT staffing and consulting excellence

Kelly Technology + Motion Recruitment, a division of Kelly Services, has been recognized as a Leader on Everest Group's 2026 U.S. IT Contingent Talent and Strategic Solutions PEAK Matrix® for its expertise in specialized IT staffing, consulting, and ...

Market News
Bullish
15 minutes ago
Sutro Biopharma to present at multiple investor conferences in November and December 2026

Sutro Biopharma to present at multiple investor conferences in November and December 2026

Sutro Biopharma, a clinical-stage oncology company specializing in antibody drug conjugates (ADCs), announced its participation in several investor conferences in November and December 2026, including events hosted by Stifel, Truist Securities, UBS, ...

Market News
Neutral
1 hour ago
etoro acquires Argentine fintech LB Finanzas to expand in Latin America

etoro acquires Argentine fintech LB Finanzas to expand in Latin America

etoro has agreed to acquire LB Finanzas, a leading Argentine all-in-one financial app, to strengthen its presence in Latin America's fast-growing fintech market. LB Finanzas offers integrated investing and payment solutions, catering to Argentine ret...

Company Fundamentals
Bullish
1 hour ago
JD.com to release Q3 2026 financial results on Nov 17 with a management call scheduled.

JD.com to release Q3 2026 financial results on Nov 17 with a management call scheduled.

JD.com announced it will publish its unaudited financial results for the third quarter of 2026 on November 17, before the U.S. market opens. The company's management will hold a conference call the same day to discuss the results, providing investors...

Company Fundamentals
Neutral
4 hours ago
KE Holdings to release Q3 2026 financial results on Nov 16 with a live earnings call.

KE Holdings to release Q3 2026 financial results on Nov 16 with a live earnings call.

KE Holdings Inc., a major online and offline housing platform in China, will announce its unaudited financial results for the third quarter of 2026 on November 16 before the U.S. market opens. The company will host an earnings conference call at 7:00...

Company Fundamentals
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App